Lumena Pharmaceuticals is developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health. The company’s clinical-stage product candidates carry a reduced risk of systemic toxicities by selectively targeting a transporter in the intestine and are designed to be minimally absorbed in the body. Lumena’s lead candidate, LUM001, has been extensively evaluated in other indications across 12 clinical studies in more than 1,400 subjects. Because of the extensive preclinical and clinical data package for a compound at this stage in development, LUM001 is positioned to rapidly progress through the clinic in pediatric and adult patients with several types of cholestatic liver disease. While Lumena’s primary focus is to develop novel treatments for patients with rare liver diseases, the company’s therapeutic approach also has promising potential in the treatment... See More
Funding Rounds (3) - $70.60MUpdate
Alta Partners is a leading venture capital firm in life sciences, funding over 130 companies in..
Early-Stage Biotech Investment
At Pappas Ventures, their sole focus is investing in the life sciences â€“ biotechnology,..
Venture Capital Firm
Adage Capital Management is a Boston-based $8.9B Money Management firm focused on managing S&P..
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences..
12531 High Bluff Drive
San Diego, CA 92130